WO/2006/065335 is referenced by 55 patents.

The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaeutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.

Title
Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
Application Number
PCT/US2005/037224
Publication Number
2006/065335
Application Date
October 17, 2005
Publication Date
June 22, 2006
Inventor
Durette Philippe L
Leone Joseph
Olsen David B
Maccoss Malcolm
Agent
MERCK 126 East Lincoln Avenue Philippe L Durette Rahway NJ 07065 0907
Assignee
Durette Philippe L
Leone Joseph
Olsen David B
Maccoss Malcolm
Merck & Co
IPC
C07H 19/14
A61K 31/7042
A61K 31/7052
View Original Source